Determination of cyclophosphamide enantiomers in plasma by LC-MS/MS: Application to pharmacokinetics in breast cancer and lupus nephritis patients
✍ Scribed by Carolina De Miranda Silva; Bruno Jose Dumêt Fernandes; Maria Paula Marques Pereira; Lucienir Maria Da Silva; Eduardo Antônio Donadi; Ângelo Do Carmo Silva Matthes; Jurandyr Moreira De Andrade; Vera Lucia Lanchote
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 170 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0899-0042
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
This article describes the enantioselective analysis of cyclophosphamide (CPA) in human plasma using LC‐MS/MS. CPA enantiomers were extracted from plasma using a mixture of ethyl acetate and chloroform (75:25, v/v). The enantiomers were separated on a Chiralcel® OD‐R column, with the mobile phase consisting of a mixture of acetonitrile and water (75:25, v/v) plus 0.2% formic acid. The protonated ions and their respective product ions were monitored using two functions, 261 > 141 for CPA enantiomers and 189 > 104 for the internal standard (antipyrine). Recovery rates were higher than 95% and the quantification limit was 2.5‐ng/ml plasma for both enantiomers. The coefficients of variation and the relative errors obtained for the validation of intra‐ and interassay precision and accuracy were less than 10%. The method was applied for the investigation of the enantioselective pharmacokinetics of CPA in a lupus nephritis patient treated with 1 g CPA infused over 2 h and in a breast cancer patient treated with 0.9 g infused over 1 h. No stereoselectivity in the pharmacokinetic parameters was observed for either patient. Clearance values of 2.63 and 2.93 l/h and of 3.36 and 3.61 l/h for (−)‐(S) and (+)‐(R)‐CPA were obtained for the breast cancer and lupus nephritis patient, respectively. Chirality, 2009. © 2008 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES